While Day One Biopharmaceuticals Inc has overperformed by 2.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DAWN rose by 24.85%, with highs and lows ranging from $18.07 to $9.67, whereas the simple moving average jumped by 24.46% in the last 200 days.
On April 24, 2024, Needham Reiterated Day One Biopharmaceuticals Inc (NASDAQ: DAWN) to Buy. A report published by BofA Securities on April 25, 2023, Downgraded its rating to ‘Underperform’ for DAWN. CapitalOne also rated DAWN shares as ‘Overweight’, setting a target price of $40 on the company’s shares in an initiating report dated February 08, 2023. H.C. Wainwright initiated its ‘Buy’ rating for DAWN, as published in its report on December 15, 2022. Needham’s report from December 14, 2022 suggests a price prediction of $40 for DAWN shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -69.97% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.93, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and DAWN is registering an average volume of 1.06M. On a monthly basis, the volatility of the stock is set at 7.90%, whereas on a weekly basis, it is put at 6.24%, with a loss of -0.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $36.89, showing growth from the present price of $17.08, which can serve as yet another indication of whether DAWN is worth investing in or should be passed over.
How Do You Analyze Day One Biopharmaceuticals Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 32.16%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 75.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DAWN shares are owned by institutional investors to the tune of 75.37% at present.
